Article

Obesity is linked to aggressive prostate cancer

Obese men with prostate cancer are more likely to have aggressive tumors and to experience cancer recurrence after surgery compared with men of normal weight or those who are overweight but not obese, according to two new studies.

Related Videos
Mohamad Baker Berjaoui, MD, answers a question during a Zoom video interview
Medcast series
Elia Abou Charaweb, MD, answers a question during a video interview
Related Content
Belzutifan nears EU approval for advanced renal cell carcinoma
December 13th 2024

Belzutifan nears EU approval for advanced renal cell carcinoma

Hannah Clarke
A final decision on marketing authorization is anticipated for Q1 of 2025.
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
FDA greenlights pivotal trial of wearable bioelectronic device for OAB
December 12th 2024

FDA greenlights pivotal trial of wearable bioelectronic device for OAB

Hannah Clarke
The primary aims for the EVANESCE-II trial are to confirm the safety of the FemPulse System and to establish noninferiority to first-line tolterodine.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
Expanded Access Program to provide real-world data on cretostimogene grenadenorepvec
December 11th 2024

Expanded Access Program to provide real-world data on cretostimogene grenadenorepvec

Hannah Clarke
Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy for patients with BCG-unresponsive high-risk NMIBC.
Sandip Prasad, MD, on UGN-102’s potential as a non-surgical option in NMIBC
December 10th 2024

Sandip Prasad, MD, on UGN-102’s potential as a non-surgical option in NMIBC

Sandip M. Prasad, MD, MPhil
"The durability response for these patients was impressive given the fact that these patients were those who, by definition and by inclusion criteria, were recurrent within a year at [baseline]," says Sandip M. Prasad, MD.
© 2024 MJH Life Sciences

All rights reserved.